We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M Turnover 28.57%
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$33.6M
Cap. Flow
+$4.33M
Cap. Flow %
3.64%
Top 10 Hldgs %
74.7%
Holding
51
New
6
Increased
12
Reduced
5
Closed
18
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.09M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.05M
3
PFE icon
Pfizer
PFE
+$1.5M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$1.35M
5
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$1.29M

Top Sells

Rank Stock Value
1
QLTI icon
QLT Inc
QLTI
+$3.48M
2
HNT
HEALTH NET INC
HNT
+$3.4M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$951K
4
BAX icon
Baxter International
BAX
+$736K
5
VIRX icon
Viracta Therapeutics, Inc. Common Stock
VIRX
+$570K

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.77%
2 Healthcare 47.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$807B
$19.6M 16.41%
100,000
– –
2013 Q2
4 quarters
TWM icon
2
CALL
ProShares UltraShort Russell2000
TWM
$70.2M
$12.9M 10.82%
15,000
+2,500
+20% +$2.38M
2013 Q4
2 quarters
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$76.2B
$11.9M 9.96%
100,000
+50,000
+100% +$5.68M
2013 Q2
4 quarters
AMRI
4
DELISTED
Albany Molecular Research Inc
AMRI
$10M 8.41%
498,200
+50,000
+11% +$847K
2014 Q1
1 quarter
AZN icon
5
AstraZeneca
AZN
$256B
$7.43M 6.23%
100,000
+42,761
+75% +$3.09M
2013 Q2
4 quarters
ANIP icon
6
ANI Pharmaceuticals
ANIP
$1.65B
$6.85M 5.75%
199,000
+65,442
+49% +$2.05M
2013 Q2
4 quarters
TEVA icon
7
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
$6.82M 5.72%
130,000
– –
2013 Q3
3 quarters
AUXL
8
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$4.6M 3.86%
229,481
+50,000
+28% +$1.15M
2013 Q2
4 quarters
DGX icon
9
Quest Diagnostics
DGX
$25.9B
$4.53M 3.8%
77,208
– –
2013 Q2
4 quarters
MRK icon
10
Merck
MRK
$363B
$4.45M 3.74%
80,696
– –
2013 Q2
4 quarters
PFE icon
11
Pfizer
PFE
$168B
$4.45M 3.73%
158,100
+52,700
+50% +$1.5M
2014 Q1
1 quarter
SNY icon
12
Sanofi
SNY
$96.5B
$3.07M 2.57%
57,735
– –
2013 Q2
4 quarters
BIS icon
13
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.99M
$2.85M 2.39%
+5,000
New +$3.44M
2014 Q2
0 quarters
BIS icon
14
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.99M
$2.85M 2.39%
5,000
+1,875
+60% +$1.29M
2014 Q1
1 quarter
SUPN icon
15
CALL
Supernus Pharmaceuticals
SUPN
$2.19B
$2.19M 1.84%
200,000
– –
2013 Q2
4 quarters
AMRI
16
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$2.01M 1.69%
100,000
– –
2014 Q1
1 quarter
AUXL
17
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$2.01M 1.68%
100,000
-200,000
-67% -$4.59M
2014 Q1
1 quarter
IPXL
18
DELISTED
Impax Laboratories, Inc.
IPXL
$1.5M 1.26%
+50,000
New +$1.35M
2014 Q2
0 quarters
SRNE
19
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.38M 1.16%
204,968
+104,968
+105% +$792K
2014 Q1
1 quarter
TWM icon
20
ProShares UltraShort Russell2000
TWM
$70.2M
$1.08M 0.9%
1,250
– –
2014 Q1
1 quarter
VIRX icon
21
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$978K 0.82%
714
+476
+200% +$552K
2014 Q1
1 quarter
KIN
22
DELISTED
Kindred Biosciences, Inc.
KIN
$932K 0.78%
+50,000
New +$849K
2014 Q2
0 quarters
SCMP
23
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$667K 0.56%
+96,630
New +$683K
2014 Q2
0 quarters
FCSC
24
DELISTED
Fibrocell Science Inc.
FCSC
$629K 0.53%
10,518
+3,333
+46% +$186K
2014 Q1
1 quarter
CEMP
25
DELISTED
Cempra, Inc.
CEMP
$537K 0.45%
+50,000
New +$483K
2014 Q2
0 quarters
1
2 3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Healthcare Value Capital held 51 positions worth $119M, down 22% from $153M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Healthcare Value Capital deployed $4.33M of net new capital in Q2 2014, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, down from 65% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Vaxart, an estimated $380K trimmed.

  • Healthcare Value Capital's largest Q2 2014 buy was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.
  • Healthcare Value Capital added most to AstraZeneca in Q2 2014, an estimated $3.09M increase.
  • Healthcare Value Capital's biggest Q2 2014 reduction was Vaxart, cutting an estimated $380K.
  • Healthcare Value Capital fully exited QLT Inc in Q2 2014, selling an estimated $3.48M.
  • Healthcare Value Capital's ten largest holdings make up 75% of its $119M portfolio in Q2 2014.
  • Healthcare Value Capital opened 6 new positions and closed 18 in Q2 2014.
  • Healthcare Value Capital's portfolio value fell 22% quarter-over-quarter to $119M.

Based on Healthcare Value Capital's 13F filing for Q2 2014, filed 13 Aug 2014.